Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma

Rare complication or incidental finding?

R. Cavalli, R. B. Buffon, M. De Souza, A. M. Colli, C. Gelmetti

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.

Original languageEnglish
Pages (from-to)106-109
Number of pages4
JournalDermatology
Volume224
Issue number2
DOIs
Publication statusPublished - May 2012

Fingerprint

Tumor Lysis Syndrome
Incidental Findings
Hemangioma
Propranolol
Electrolytes
Hyperphosphatemia
Hyperkalemia
Therapeutics
Phosphorus
Potassium
Maintenance
Serum

Keywords

  • Hemangioma
  • Hyperkalemia
  • Infancy
  • Propranolol
  • Tumor lysis syndrome

ASJC Scopus subject areas

  • Dermatology

Cite this

Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma : Rare complication or incidental finding? / Cavalli, R.; Buffon, R. B.; De Souza, M.; Colli, A. M.; Gelmetti, C.

In: Dermatology, Vol. 224, No. 2, 05.2012, p. 106-109.

Research output: Contribution to journalArticle

@article{5e43a69c898e4675851ab43805a61c68,
title = "Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: Rare complication or incidental finding?",
abstract = "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.",
keywords = "Hemangioma, Hyperkalemia, Infancy, Propranolol, Tumor lysis syndrome",
author = "R. Cavalli and Buffon, {R. B.} and {De Souza}, M. and Colli, {A. M.} and C. Gelmetti",
year = "2012",
month = "5",
doi = "10.1159/000337553",
language = "English",
volume = "224",
pages = "106--109",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma

T2 - Rare complication or incidental finding?

AU - Cavalli, R.

AU - Buffon, R. B.

AU - De Souza, M.

AU - Colli, A. M.

AU - Gelmetti, C.

PY - 2012/5

Y1 - 2012/5

N2 - A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.

AB - A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.

KW - Hemangioma

KW - Hyperkalemia

KW - Infancy

KW - Propranolol

KW - Tumor lysis syndrome

UR - http://www.scopus.com/inward/record.url?scp=84861895860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861895860&partnerID=8YFLogxK

U2 - 10.1159/000337553

DO - 10.1159/000337553

M3 - Article

VL - 224

SP - 106

EP - 109

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -